Lead FX-322 study investigator, Susan King, will be presenting the latest FX-322 clinical trial results publicly, for the first time, this September. She will be joined by her six co-authors – including Will McLean, Co-Founder of Frequency Therapeutics.
The new FX-322 results and supporting data that will be referenced in Susan King’s scientific presentation, “Phase 1/2 Hearing Loss Trial of Intratympanic FX322, a Progenitor Cell Activator,” are not yet public. They have not yet been published. Both abstract and full text are currently “embargoed information” (and unlikely to be available online or in print until mid September, at the earliest).
Where FX-322 is “at” right now…
Last month, on April 9th, Frequency Therapeutics announced in a press release the positive results of their Phase 1/2 safety trial of FX-322. The company also shared its plans to present these very exciting human trial results “at a major otolaryngology meeting in 2019.”
This was great news… but they did not give us any other details. They did not tell us which otolaryngology meeting. They did not give us a date. They did not give us much. Instead, all we got was a hint…
Which is perhaps why so many people have been feeling in the dark about FX-322 recently… and also why so many people are getting hungry for updates.
Well, now we have an update that eliminates some of this looming uncertainty…
UPDATE: The date has been changed from September 18 to September 17. The information in this post, including location, date, and time, have been changed since this post was first published.
Title: Phase 1/2 Hearing Loss Trial of Intratympanic FX322, a Progenitor Cell Activator
Session: Scientific Oral Presentations: Otology/ Neurology
Location: Ernest N. Morial Convention Center, New Orleans Theater A
Date: Wednesday, Sep 18 9:21 AM
The most exciting part?
September 18 and the official release of the study results will act as a trigger for some even bigger updates. For example, the FX-322 Phase 2a clinical trial can only be initiated once the previous part of the study’s results are submitted for review and confirmed. So, we can probably expect yet another announcement about the status of Phase 2a, shortly after this presentation.
That’s all for now.
More information about AAO-HNSF 2019:
September 15 – 18, 2019
New Orleans, LA
About the Meeting:
The AAO-HNSF Annual Meeting & OTO Experience is “the world’s best gathering of otolaryngologists.” Held each fall, the AAO-HNSF Annual Meeting & OTO Experience provides an opportunity for thousands of Academy members, non-member physicians, allied health professionals, administrators, and exhibiting companies to converge for an exhilarating four days.
UPDATE (schedule has been changed):
For exclusive updates about FX-322 and other not-yet-available tinnitus treatments, subscribe to email updates. For a full list of previous FX-322 updates, all on one page, go here: https://www.tinnitustreatmentreport.com/tag/fx-322/
MESSAGE FROM ADMIN: “This exclusive update is made possible thanks to TinnitusTreatmentReport.com’s automated treatment tracking system. Behind-the-scenes, this system monitors hundreds of sources 24/7, and automatically collects relevant links and updates about tinnitus for posting on this site. Some of these updates become exclusive posts, like the one you are reading. Most remain as links, which are added to the front page and subject to occasional human review. Send feedback to firstname.lastname@example.org if you want to help improve this website. Requests and suggestions are welcome. – Michael”